Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ‐47965567
British Journal of Pharmacology2013Vol. 170(3), pp. 624–640
Citations Over TimeTop 10% of 2013 papers
Anindya Bhattacharya, Qi Wang, Hong Ao, James R. Shoblock, Brian Lord, Leah Aluisio, Ian Fraser, Diane Nepomuceno, Robert A. Neff, Natalie Welty, Timothy W. Lovenberg, Pascal Bonaventure, Alan D. Wickenden, Michael A. Letavic
Abstract
JNJ-47965567 is centrally permeable, high affinity P2X7 antagonist that can be used to probe the role of central P2X7 in rodent models of CNS pathophysiology.
Related Papers
- → Peptide cholesystokinin receptor antagonist increases food intake in rats(1995)30 cited
- → The novel 5-HT4 receptor antagonist DAU 6285 antagonizes 5-hydroxytryptamine-induced tachycardia in pigs(1993)8 cited
- → Cimetidine's effect on dermal H1‐receptor antagonist tolerance.(1985)
- The role of BN52021 in the hemodynamics in rat random skin flap(2001)
- Research advances in PAF and its receptor antagonist(2011)